<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7233228\results\search\disease\results.xml">
  <result pre="Hospital and Research Centre pmcid: 7233228S2352-6467(20)30042-9 doi: 10.1016/j.ijpam.2020.05.001 : Article" exact="Pediatric" post="COVID-19: An update on the expanding pandemic Al-HajjarSamihajjar@kfshrc.edu.saabâˆ—[a], [b],"/>
  <result pre="access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). The coronavirus" exact="disease" post="of 2019 (COVID-19)[1] is caused by a novel and"/>
  <result pre="caused by a novel and highly contagious virus termed â€œSevere" exact="Acute" post="Respiratory Syndrome Coronavirus Two,â€� or â€œSARS-CoV-2â€� [2]. The virus"/>
  <result pre="by a novel and highly contagious virus termed â€œSevere Acute" exact="Respiratory" post="Syndrome Coronavirus Two,â€� or â€œSARS-CoV-2â€� [2]. The virus was"/>
  <result pre="a novel and highly contagious virus termed â€œSevere Acute Respiratory" exact="Syndrome" post="Coronavirus Two,â€� or â€œSARS-CoV-2â€� [2]. The virus was first"/>
  <result pre="patients with advanced age or with preexisting medical comorbidities, including" exact="cardiovascular" post="diseases, diabetes, hypertension, chronic respiratory disease and cancer [6]."/>
  <result pre="or with preexisting medical comorbidities, including cardiovascular diseases, diabetes, hypertension," exact="chronic" post="respiratory disease and cancer [6]. Currently over five and"/>
  <result pre="with preexisting medical comorbidities, including cardiovascular diseases, diabetes, hypertension, chronic" exact="respiratory" post="disease and cancer [6]. Currently over five and a"/>
  <result pre="preexisting medical comorbidities, including cardiovascular diseases, diabetes, hypertension, chronic respiratory" exact="disease" post="and cancer [6]. Currently over five and a half"/>
  <result pre="comorbidities, including cardiovascular diseases, diabetes, hypertension, chronic respiratory disease and" exact="cancer" post="[6]. Currently over five and a half million people"/>
  <result pre="Children of all ages are susceptible but have experienced a" exact="lower" post="incidence of COVID-19 disease. Data from the Chinese Center"/>
  <result pre="incidence of COVID-19 disease. Data from the Chinese Center for" exact="Disease" post="Control and Prevention suggest that less than 1% of"/>
  <result pre="very unusual [6,8]. The SARS-CoV-2 virus is transmitted mainly via" exact="respiratory" post="droplets [9]. Nearly 90% of children with COVID-19 were"/>
  <result pre="important drivers of epidemics in the community [11,12]. A very" exact="limited" post="number of infections have been reported in infants and"/>
  <result pre="epidemics in the community [11,12]. A very limited number of" exact="infections" post="have been reported in infants and neonates. At the"/>
  <result pre="although, because of the small number of reported cases of" exact="infection" post="during the first trimester (when embryogenesis occurs), a risk"/>
  <result pre="during the first trimester (when embryogenesis occurs), a risk of" exact="congenital" post="anomalies associated with COVID-19 cannot be completely excluded [16]."/>
  <result pre="be completely excluded [16]. Data and prior experience with other" exact="respiratory" post="viruses (e.g. influenza, SARS-CoV-1, MERS) suggest that antenatal transplacental"/>
  <result pre="with other respiratory viruses (e.g. influenza, SARS-CoV-1, MERS) suggest that" exact="antenatal" post="transplacental transmission via maternal viremia is unlikely [13]. Analyses"/>
  <result pre="fluid and breastmilk from pregnant women confirmed to have COVID-19" exact="infections" post="have found no evidence of SARS-CoV-2 infections [[13], [14],"/>
  <result pre="to have COVID-19 infections have found no evidence of SARS-CoV-2" exact="infections" post="[[13], [14], [15], [16]]. On the other hand, newborn"/>
  <result pre="hand, newborn infants may remain at high risk postnatally for" exact="infection" post="through maternal respiratory secretions. There have now been several"/>
  <result pre="may remain at high risk postnatally for infection through maternal" exact="respiratory" post="secretions. There have now been several series of COVID-19"/>
  <result pre="fever, 48.5% had coughing, and 46% pharyngeal erythema. Radiologically proven" exact="pneumonia" post="was present in 111 (65%), but only 4 (2.3%)"/>
  <result pre="had hypoxemia with oxygen saturation &amp;lt;92%. Twelve children with radiologic" exact="pneumonia" post="were asymptomatic [18]. Other less common reported symptoms in"/>
  <result pre="COVID-19 and included influenza viruses A and B, Mycoplasma pneumoniae," exact="respiratory" post="syncytial virus, and cytomegalovirus [19]. Reverse transcription polymerase chain"/>
  <result pre="recommended method for the confirmation of a COVID-19 infection, using" exact="upper" post="respiratory specimens (nasopharyngeal and/or pharyngeal swabs) or, if they"/>
  <result pre="method for the confirmation of a COVID-19 infection, using upper" exact="respiratory" post="specimens (nasopharyngeal and/or pharyngeal swabs) or, if they can"/>
  <result pre="(nasopharyngeal and/or pharyngeal swabs) or, if they can be obtained," exact="lower" post="respiratory specimens [20,21]. High viral load from the nasopharynx"/>
  <result pre="and/or pharyngeal swabs) or, if they can be obtained, lower" exact="respiratory" post="specimens [20,21]. High viral load from the nasopharynx was"/>
  <result pre="if they can be obtained, lower respiratory specimens [20,21]. High" exact="viral" post="load from the nasopharynx was reported in an infant"/>
  <result pre="remained positive for up to 16 days [22]. There is" exact="limited" post="information on laboratory findings in children with COVID-19. In"/>
  <result pre="had neutrophilia, 6% had neutropenia, and 3% reported lymphocytopenia [23,24]." exact="Lymphocytopenia" post="was reported in more than 80% of critically ill"/>
  <result pre="critically ill adults with COVID-19 suggesting that the severity of" exact="Lymphocytopenia" post="correlated with the severity of infection [25]. The low"/>
  <result pre="that the severity of Lymphocytopenia correlated with the severity of" exact="infection" post="[25]. The low frequency of lymphopenia in children may"/>
  <result pre="with the severity of infection [25]. The low frequency of" exact="lymphopenia" post="in children may be, at least in part, due"/>
  <result pre="elevated in 13.6% and 10.6% of cases, respectively [23]. Elevation" exact="of liver" post="enzymes, muscle enzymes and myoglobin, and an increased level"/>
  <result pre="and 10.6% of cases, respectively [23]. Elevation of liver enzymes," exact="muscle" post="enzymes and myoglobin, and an increased level of D-dimer"/>
  <result pre="The radiological changes in the lungs of children with COVID-19" exact="pneumonia" post="have not been fully characterized. In a study of"/>
  <result pre="study of 171 children with PCR-confirmed COVID-19, 15.8% of patientsâ€™" exact="chest" post="radiographs were read as normal [18]. Common computed tomography"/>
  <result pre="normal [18]. Common computed tomography abnormalities in these children were" exact="bilateral" post="ground glass opacities in 32.7%, local patchy shadowing in"/>
  <result pre="had at least one underlying condition. The most common were" exact="chronic" post="lung disease (including asthma) in 40, cardiovascular disease in"/>
  <result pre="at least one underlying condition. The most common were chronic" exact="lung disease" post="(including asthma) in 40, cardiovascular disease in 25 and"/>
  <result pre="least one underlying condition. The most common were chronic lung" exact="disease" post="(including asthma) in 40, cardiovascular disease in 25 and"/>
  <result pre="most common were chronic lung disease (including asthma) in 40," exact="cardiovascular disease" post="in 25 and immunosuppression in 10 [8]. Furthermore, among"/>
  <result pre="common were chronic lung disease (including asthma) in 40, cardiovascular" exact="disease" post="in 25 and immunosuppression in 10 [8]. Furthermore, among"/>
  <result pre="less than 1 year of age to reach 10.6%.17. The" exact="lower" post="incidence of symptomatic and severely symptomatic COVID-19 in children"/>
  <result pre="year of age to reach 10.6%.17. The lower incidence of" exact="symptomatic" post="and severely symptomatic COVID-19 in children compared to adults"/>
  <result pre="to reach 10.6%.17. The lower incidence of symptomatic and severely" exact="symptomatic" post="COVID-19 in children compared to adults seems counterintuitive and"/>
  <result pre="be due to childrenâ€™s younger immune systems and/or to a" exact="lower" post="expression of ACE2 receptor cells [27]. Another possible explanation"/>
  <result pre="of ACE2 receptor cells [27]. Another possible explanation is that" exact="respiratory" post="viral diseases are childhood diseases that often re-infect throughout"/>
  <result pre="ACE2 receptor cells [27]. Another possible explanation is that respiratory" exact="viral" post="diseases are childhood diseases that often re-infect throughout life."/>
  <result pre="[27]. Another possible explanation is that respiratory viral diseases are" exact="childhood" post="diseases that often re-infect throughout life. Thus, essentially all"/>
  <result pre="throughout life. Thus, essentially all adults already have immunity. Parenthetically," exact="systemic" post="viral diseases with a respiratory component, such as measles"/>
  <result pre="life. Thus, essentially all adults already have immunity. Parenthetically, systemic" exact="viral" post="diseases with a respiratory component, such as measles and"/>
  <result pre="adults already have immunity. Parenthetically, systemic viral diseases with a" exact="respiratory" post="component, such as measles and varicella, are also often"/>
  <result pre="Parenthetically, systemic viral diseases with a respiratory component, such as" exact="measles" post="and varicella, are also often more severe in non-immune"/>
  <result pre="of supportive treatments including antipyretics, oxygen therapy and antibiotics for" exact="secondary" post="bacterial infections [26]. Clinical trials are also being conducted"/>
  <result pre="supportive treatments including antipyretics, oxygen therapy and antibiotics for secondary" exact="bacterial infections" post="[26]. Clinical trials are also being conducted globally, with"/>
  <result pre="treatments including antipyretics, oxygen therapy and antibiotics for secondary bacterial" exact="infections" post="[26]. Clinical trials are also being conducted globally, with"/>
  <result pre="requiring supplemental or mechanical ventilation) [29]. A panel of pediatric" exact="infectious disease" post="physicians and pharmacists from North America has recommended Remdesivir"/>
  <result pre="supplemental or mechanical ventilation) [29]. A panel of pediatric infectious" exact="disease" post="physicians and pharmacists from North America has recommended Remdesivir"/>
  <result pre="COVID-19 testing [34]. This recommendation was subsequently endorsed by The" exact="Pediatric" post="Infectious Diseases Society. Hydroxychloroquine may be considered (with careful"/>
  <result pre="testing [34]. This recommendation was subsequently endorsed by The Pediatric" exact="Infectious" post="Diseases Society. Hydroxychloroquine may be considered (with careful consideration"/>
  <result pre="[34]. This recommendation was subsequently endorsed by The Pediatric Infectious" exact="Diseases" post="Society. Hydroxychloroquine may be considered (with careful consideration of"/>
  <result pre="There have, however, been several recent reports of a Multi-Inflammatory" exact="Syndrome" post="in Children (MIS-C) with features that in some subjects"/>
  <result pre="Children (MIS-C) with features that in some subjects resemble Kawasaki" exact="Disease" post="or Kawasaki Shock Syndrome [35,36]. The patients who present"/>
  <result pre="features that in some subjects resemble Kawasaki Disease or Kawasaki" exact="Shock" post="Syndrome [35,36]. The patients who present with this symptom"/>
  <result pre="that in some subjects resemble Kawasaki Disease or Kawasaki Shock" exact="Syndrome" post="[35,36]. The patients who present with this symptom complex"/>
  <result pre="patients who present with this symptom complex do not have" exact="pneumonia" post="but often have SARS-CoV-2 identified by PCR in upper"/>
  <result pre="have pneumonia but often have SARS-CoV-2 identified by PCR in" exact="upper" post="respiratory samples or antibody evidence of past SARS-CoV-2 infection."/>
  <result pre="pneumonia but often have SARS-CoV-2 identified by PCR in upper" exact="respiratory" post="samples or antibody evidence of past SARS-CoV-2 infection. References"/>
  <result pre="briefing on 2019-nCoV on 11 February 2020Available at:https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 2GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.Severe" exact="acute" post="respiratory syndrome-related coronavirus: the species and its virusesâ€&quot;a statement"/>
  <result pre="on 2019-nCoV on 11 February 2020Available at:https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 2GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.Severe acute" exact="respiratory" post="syndrome-related coronavirus: the species and its virusesâ€&quot;a statement of"/>
  <result pre="at:https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020 6WuZunyouMcGooganJennifer M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China. Summary of a report"/>
  <result pre="report of 72 314 cases from the Chinese. Center for" exact="disease" post="Control and preventionJ Am Med Assoc3231320201239124210.1001/jama.2020.2648 7Hopkins UniversityJohnCOVID-19 resource"/>
  <result pre="Assoc3231320201239124210.1001/jama.2020.2648 7Hopkins UniversityJohnCOVID-19 resource centerhttps://coronavirus.jhu.edu/map.html 8collab: CDC, COVID-19 Response TeamCoronavirus" exact="disease" post="in children-United States february 12-april 2, 2020MMWR(Morb Mortal Wkly"/>
  <result pre="2, 2020MMWR(Morb Mortal Wkly Rep)69April 6, 2020 9CaoQingChing ChenYi-Chenb Chyi-LiangChiuCheng-HsunSARS-CoV-2" exact="infection" post="in children: transmission dynamics and clinical characteristicsJ Formos Med"/>
  <result pre="Assoc1192020670e67332139299 10QiuH.WuJ.HongL.LuoY.SongQ.ChenD.Clinical and epidemiological features of 36 children with coronavirus" exact="disease" post="2019 (COVID-19) in Zhejiang, China: an observational cohort studyLancet"/>
  <result pre="cohort studyLancet Infect Dis2020 Mar 25 11MimuraS.KamigakiT.TakahashiY.UmenaiT.KudouM.OshitaniH.Role of preschool and" exact="primary" post="school children in epidemics of influenza A in a"/>
  <result pre="their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus" exact="infections" post="and pregnancy outcomesArch Pathol Lab Med Mar202010.5858/arpa.2020-0901-SA[Epub ahead of"/>
  <result pre="17 15ChenH.GuoJ.WangC.LuoF.YuX.ZhangW.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="101731439918 17DongY.MoX.HuY.QiX.JiangF.JiangZ.Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus" exact="disease" post="in ChinaPediatrics2020 Mar 1 18LuX.ZhangL.DuH.ZhangJ.LiY.Y.QuJ.SARS-CoV-2 infection in childrenN Engl"/>
  <result pre="patients with 2019 coronavirus disease in ChinaPediatrics2020 Mar 1 18LuX.ZhangL.DuH.ZhangJ.LiY.Y.QuJ.SARS-CoV-2" exact="infection" post="in childrenN Engl J Med2020 Mar 18 19XiaW.ShaoJ.GuoY.PengX.LiZ.HuD.Clinical and"/>
  <result pre="from adultsPediatr Pulmonol5552020 May1169117432134205 20World Health OrganizationLaboratory testing for coronavirus" exact="disease" post="(COVID-19) in suspected human casesInterim Guid2 March 2020Available at:https://apps.who.int/iris/bitstream/handle/10665/331501/WHO-COVID-19-laboratory-2020.5-eng.pdf?sequence=1&amp;amp;isAllowed=y"/>
  <result pre="ahead of print] 22KamK.Q.YungC.F.CuiL.Tzer Pin LinR.MakT.M.MaiwaldM.A well infant with coronavirus" exact="disease" post="2019 with high viral load2020Clinical Infectious Diseases 23LudvigssonJ.F.Systemic review"/>
  <result pre="Pin LinR.MakT.M.MaiwaldM.A well infant with coronavirus disease 2019 with high" exact="viral" post="load2020Clinical Infectious Diseases 23LudvigssonJ.F.Systemic review of COVID-19 in children"/>
  <result pre="well infant with coronavirus disease 2019 with high viral load2020Clinical" exact="Infectious" post="Diseases 23LudvigssonJ.F.Systemic review of COVID-19 in children shows milder"/>
  <result pre="infant with coronavirus disease 2019 with high viral load2020Clinical Infectious" exact="Diseases" post="23LudvigssonJ.F.Systemic review of COVID-19 in children shows milder cases"/>
  <result pre="prognosis than adults202010.1111/APA.15270 24HenryB.M.LippiG.PlebaniM.Laboratory abnormalities in children with novel coronavirus" exact="disease" post="2019Clin Chem Lab Med2020 Mar 161(ahead-of-print) 25YangX.YuY.XuJ.ShuH.LiuH.WuY.Clinical course and"/>
  <result pre="25YangX.YuY.XuJ.ShuH.LiuH.WuY.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir"/>
  <result pre="Respir Med2020 Feb 24 26ChenZ.M.FuJ.F.ShuQ.ChenY.H.HuaC.Z.LiF.B.Diagnosis and treatment recommendations for pediatric" exact="respiratory" post="infection caused by the 2019 novel coronavirusWorld J Pediat2020"/>
  <result pre="Med2020 Feb 24 26ChenZ.M.FuJ.F.ShuQ.ChenY.H.HuaC.Z.LiF.B.Diagnosis and treatment recommendations for pediatric respiratory" exact="infection" post="caused by the 2019 novel coronavirusWorld J Pediat2020 Feb"/>
  <result pre="for Potential COVID-19 TreatmentAvailable at:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatmentMay,1,2020 30National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID). Adaptive COVID-19 treatment trial, shows Remdesivir accelerates"/>
  <result pre="Potential COVID-19 TreatmentAvailable at:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatmentMay,1,2020 30National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID). Adaptive COVID-19 treatment trial, shows Remdesivir accelerates recovery"/>
  <result pre="Dis Soc2020 Apr 22 35VerdoniL.MazzaA.GervasoniA.MartelliL.An outbreak of severe Kawasaki like" exact="disease" post="at the Italian epicentre of the SARS-CoV-2 epidemic: an"/>
 </snippets>
</snippetsTree>
